Colonic basidiobolomycosis in a child: report of a culture-proven case

Zabolinejad, Nona; Naseri, Ali; Davoudi, Y; Joudi, Marjan; Aelami, Mohammad Hassan

doi:10.1016/j.ijid.2013.11.016

Cited by 14 publications

(27 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as suggested by Bering et al, the absence of demonstrable in vitro activity of KI against B. ranarum coupled with several possible limitations (toxicity associated with high doses, lack of any standard prescription recommendation, available new azoles) do not recommend its use in GIB [68]. More recently successful treatments with voriconazole [42,49,50,[53][54][55]58,59] and posaconazole [40,48,50] have been reported. On the basis of the experience reported in the literature azoles should be considered the drugs of choice for GIB.…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal basidiobolomycosis: An emerging mycosis difficult to diagnose but curable. Case report and review of the literature

Pezzani

Cristo

Parravicini

et al. 2019

Travel Medicine and Infectious Disease

View full text Add to dashboard Cite

Background: Gastrointestinal basidiobolomycosis (GIB) is a rare mycosis affecting almost exclusively immunocompetent subjects. Methods: We describe a case of GIB caused by Basidiobolus ranarum in a 25-year-old Italian immunocompetent man resident in Ireland who presented a 2-month history of epigastric pain. Suspecting colon cancer he underwent a right hemicolectomy subsequently leading to a diagnosis of GIB by means of molecular biology. After surgery a 9-month therapy with itraconazole was employed with a good outcome. A review of medical literature regarding GIB cases published in the period 1964-2017 is presented. Results: One-hundred and two cases of GIB were included in this analysis. The disease was observed predominantly in male gender (74.5%) and children (41.2%). Abdominal pain was the single most common complaint (86.3%) followed by fever (40.2%) and evidence of an abdominal mass (30.4%). Peripheral blood eosinophilia was detected in 85.7% of cases. Most of the patients were diagnosed in Saudi Arabia (37.2%) followed by USA (21.6%) and Iran (20.6%). Surgery plus antifungal therapy was employed in the majority of patients (77.5%). An unfavourable outcome was documented globally in 18.6% of patients. Conclusions: GIB seems to be an emerging intestinal mycosis among immunocompetent patients living in the Middle East and Arizona. 1 MDP and VDC contributed equally to this work.

show abstract

Section: Discussionmentioning

confidence: 99%

Gastrointestinal basidiobolomycosis: An emerging mycosis difficult to diagnose but curable. Case report and review of the literature

Pezzani

Cristo

Parravicini

et al. 2019

Travel Medicine and Infectious Disease

View full text Add to dashboard Cite

show abstract

“…The azoles antifungal group are consider the best choice for basidiobolomycosis while amphotericin showed treatment failure. Itraconazole is the most frequently used antifungal to treat gastrointestinal basidiobolomycosis.recently, Voriconazole and Posaconazole showed to be effective treatment [16] , [17] .death and recurrence has been reported in some cases [7] .…”

Section: Discussionmentioning

confidence: 99%

Pediatric gastrointestinal basidiobolomycosis mimicking malignancy

Almoosa

Alsuhaibani

Al-Dandan

et al. 2017

Medical Mycology Case Reports

View full text Add to dashboard Cite

Basidiobolomycosis is a rare fungal infection with high prevalence in southwestern province of Saudi Arabia (Tohama region); it mainly causes subcutaneous infections and rarely gastrointestinal disease. Because of its indolent presentation, it is often misdiagnosed as IBD, tuberculosis or Malignancy.We are reporting a 7 year old Saudi girl with abdominal mass, fever and eosinophilia resembling malignancy on radiological and pathological picture fully recovered with only medical therapy in the form of oral Voriconazole 2012 Elsevier Ltd. All rights reserved.

show abstract

“…Pediatric colonic basidiobolomycosis is a rare fungal infection of the colon caused by Basidiobolus ranarum (1). The case presented is unique as it is the first report of a child from the United Arab Emirates and also the first report of the use of pan fungal PCR followed by sequencing of the product to rapidly confirm the diagnosis not only by molecular confirmation of the isolate identification but also by detection of fungal DNA, directly from the colonic biopsy material.…”

Section: Discussionmentioning

confidence: 96%

Colonic Basidiobolomycosis—An Unusual Presentation of Eosinophilic Intestinal Inflammation

et al. 2020

View full text Add to dashboard Cite

Basidiobolomycosis is a rare fungal disease caused by Basidiobolus ranarum. Involvement of the gastrointestinal tract is unusual and poses both a diagnostic and therapeutic challenge, as clinical signs are non-specific and predisposing risk factors are lacking. It can mimick inflammatory bowel disease, primary immunodeficiency, or a malignancy and should be considered in patients who do not respond to standard therapy. We present the case of a 22 months old boy with confirmed colonic Basidiobolomycosis, who presented with severe eosinophilic inflammation of the gastrointestinal tract. Panfungal PCR performed on DNA extracted directly from a tissue sample confirmed the presence of Basidiobolus. He made a full recovery with a combination of surgery and prolonged targeted antifungal medication.

show abstract

Colonic basidiobolomycosis in a child: report of a culture-proven case

Cited by 14 publications

References 5 publications

Gastrointestinal basidiobolomycosis: An emerging mycosis difficult to diagnose but curable. Case report and review of the literature

Gastrointestinal basidiobolomycosis: An emerging mycosis difficult to diagnose but curable. Case report and review of the literature

Pediatric gastrointestinal basidiobolomycosis mimicking malignancy

Colonic Basidiobolomycosis—An Unusual Presentation of Eosinophilic Intestinal Inflammation

Contact Info

Product

Resources

About